-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LsyEKYj4spXOF1mnaU4gdW/2LpvD5F31ptAxWc2sLcjj78zIC9r0Z/6k3CukcmRA 4siqMZfYI53rcGxCL6uv9A== 0001144204-09-003649.txt : 20090127 0001144204-09-003649.hdr.sgml : 20090127 20090127165700 ACCESSION NUMBER: 0001144204-09-003649 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20090127 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20090127 DATE AS OF CHANGE: 20090127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENCISION INC CENTRAL INDEX KEY: 0000930775 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 841162056 STATE OF INCORPORATION: CO FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11789 FILM NUMBER: 09548730 BUSINESS ADDRESS: STREET 1: 4828 STERLING DR CITY: BOULDER STATE: CO ZIP: 80302 BUSINESS PHONE: 3034442600 MAIL ADDRESS: STREET 1: 4828 STERLING DR CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: ELECTROSCOPE INC DATE OF NAME CHANGE: 19960502 8-K 1 v137870_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)
January 27, 2009
 
ENCISION, INC.
(Exact name of registrant as specified in its charter)
     
Colorado
0-28604
84-1162056
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
     
6797 Winchester Circle, Boulder, Colorado
80301
(Address of principal executive offices)
(Zip Code)
   
Registrant’s telephone number, including area code
(303) 444-2600
   
 
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
Item 2.02  
Results of Operations and Financial Condition

The following information is furnished pursuant to Item 2.02, “Results of Operations and Financial Condition,” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

On January 27, 2009, ENCISION, INC., issued a press release announcing its financial results for the third quarter ended December 31, 2008.  A copy of the press release is attached hereto as Exhibit 99.1.

The information contained in this Current Report, including the exhibit, shall not be incorporated by reference into any filing of ENCISION, INC., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01
Financial Statements and Exhibits.

(d) 
Exhibits.

99.1 
Press Release issued by ENCISION, INC., January 27, 2009.
 

 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
ENCISION, INC.
(Registrant)
 
     
       
Date January 27, 2009
By:
/s/ Marcia K. McHaffie  
   
Marcia K. McHaffie
Controller
Principal Accounting Officer
 
 

GRAPHIC 2 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`*@$C`P$1``(1`0,1`?_$`-(```("`@,!`0`````` M```````)"@L'"`,$!08"`0$``@,!`0$`````````````!`4!`@8#!P@0```$ M!0$$!`8(#@P/``````$"!08``P0'"!$A,1()0146"E%A<2(3%X&A,A0EMSAX M\)&QP>%"4C0U12=7UQK1(R15M59GEQ@H&3DS=&5U)D9VEK;&-T=W:"D1``(` M!`,%!`<$!P@#```````!$0(#!"$Q!?!!46$&<=$2$X&1H<$B8A2Q\5('X3)R M@M(S8T+"XG/#TR0T%187_]H`#`,!``(1`Q$`/P!R4KO1W+U--"GE6^RFDSZC MH/:E`3P$0#>/Y0M0\H#$F"WG'T]9NIG%2KUKN/1'O0>`)M[`R;$1_DY9X>/H MN0$,CW_]AN:*^-8=J_A..5WH+E]F_P`"P,D-WYN&<&SV+DZCLB-D6U+5U6F2 MW/;@,ZP'YC%C^8RT7N_[+-M_HR=;IRIK76:2YC=1DI3%5FHQ5L!12-]RNP#E M`IA$=H&V;`$1V,RRE:JJ.XV^NYKCV8#ZJ:0*MM-2\:,BLI3?1#'#4K&*5S.CK]P%+^*P$#:!TCOT3*> MQO)5>3)818Z(>'I#VQC;$G^1*S]`)2E\4:Y#"DN0CZU?/2Q&N_F%)PT:K(OC M)NE4W4?=HR+RJSDB6U0*LEHC;4KK,, MJ2W%)S+I!ZE13+K?+]G;&<8 MECA4[#0+/CF!6=Y?%K&K=B]*`_%QKN]\$8-)2V^3$=35R+!D1P+90]$ON-J$ M`HD0C;0..T--!WQAQ,_1J.W>=+E\ M<[A;@W<`+.7;<3_=MUTQ)3:U7:=M&?VF4T,J\8W49UU>&:UVR@^E]T&IM0`0 MU`!U"/:!4:W45&YE<<(1[ MEC`W>+$EYL\\O%7`V^*CCU=UK7I<+S3&>W'G5UENV@DJJ8"4O"8)0@==Q\1LML7\AW9MDPKE-N14@D7#9#4?; M?IE4HRU$$MQHTI?0^M_.,)1X)H;=?=1I-\6*R))DV9,"6&WZ/L1"J7$M#"8S MS%C9)\QAAV@KJYGL)+D/][TA@I%4:58!-;B(I&(`?MJR:47KLQ3"/FETW`.N MT0CA=8ZVH4)7!_;N_S;R'=_ET' M)MCBO_IJI388[?Y1M]!/M]XQ+&WF#V[O*MI##=Z69A7!7-:5'H@J^LVVOB`# MYJ$ME`H3!'H`=_ACM>E^HE<3J5X1A[OEYGE6EP=I&'F>=)Y M&4,&,/KK8\WUN5<)XO&2DMITM!5;0VL2W(1Q-Q?V<&.#/R$H62IVHJ;D=2W M(2+F5B,FL84OJ5_;'QZP!`(DG$=-ZM:WLT(9N&_N7(G43<-.0M*E2/06_P"7 M@&F[1RV;VA_O&'3`[.ZM[6?XII?;-R,M,WEBXK8@O]!"L&D!PL M9L6X<26*@70HHX+C>]*43B;[7773;LB-AN(-/2):4R:CAMQ-X\>\6L>,6T!> M0<>[.L"SJ,ZE@7(Y$RWZ21,3EI8,0`ZUFD*8`&88##N#0`C.18RI4U#5=UC<=;[7L1KKW&L"W%%R+./[<2[F MN2C9-;^4Q";'7(CVT0P$=]IP#\4QIB&2;VR)7/**[P6"\5LX[Y_ MNXJ>JU14Q&MMDS6B)4IQ&*40*B79X=.HW"'%L5#>54TWQE,O]`U[Z]^%XN,- MOA1,'"?2J-"6?3S@GTU13A4TU53CL,0=H'(8.G;]88R\3H;M1D:>?W%=!@?) M]#S_`)OC_P"YF4'U;NQH0*6C^3,IMRV_$6.N@:?1Y/K1M%Q+&5*10($_>J5* MHJ\U<=DJ;/TIJ7&X*ZBH]G[N4_6<_=`#R`AP<""ZN.8V7EM#A[87+3175288X`(B@7&X0+J3PZ[/)J@C/F-[S>G^P6Y M3^GR.65I_M9=#](T8)LR55]75TA-P5LW6SY7%34N3K4&JTZ"F9 M#]^N$&L$^)0:]KCT]))XQ[OE?(\CNHPSYN%%]*R?LGGR35BC2A]J'JKM.;4! M\.H1J7E+)=A*8-O'Z.B-ED2ED5M64Z9;]W<_.XR3?T$-1LZIYEM=$NF5ZU8) MC8!A!V?`"K:V&SLX#;]J/FT^]?7"S= M===-WK&TTU\<8Q)M;2_.LI8<$_;VG!_17[N>$K7WER^M=/SV,S])&NGUXC&: M6C^5,IMRV_$8IY37)ZLCCKD#7Y86WS69.0"Q3)3[1#-*SHLU1MG0)#ZTU2%I M`=/V8I4XW,Y?QB[ MJ>R-K3`.@;A9;]$(G4MQR745RZ,R2]&T.9/;PE^1QB?\VRQGQ9MV(M*9STXO MG[CK$?+YMW85;-8_/=R(A@IW"HF3FPVZPO"'O%37^(`5C!H(APD]^;M!$0#H MU".6ZCN71;2R@QE@1;8_+WG5=1G4L=_+CZ.)T?U"X[>HW&QQP[>]_)7:.?/[ M%6Y30$5=ZJM'YPZ!J/46H@"_T!J(@&HQVVC?E^]1E4[R<(^S^HC5W,JPWC*& M&L6"M!*J$K%''I_Y'N"F`*%7N"WJ,!;-:("(ZA=5P!V8$=!_%.H1]1L.G?\` MQTZGER4,?5\SX%95;@V\&,;M0Z'2[+?MYPOIF3[P7TG*CRY-I_JVP?CEM\(=&S?$F9 M0<"OUFN[:BIUE^A=I7JV?LKD_16[<^7=B9+KID+&M],6D<5P&16AVHMJI+:, M5=1'J`:[6V7C`!50W:AX8U^PI=.ZBG3?!;?A)B7*6Y\K:R3!LXZ9DKC(K?N`/#H(!HC+.HB42G^#X)GKI6O.^FA-QV M_LHDO7%_Z?OGQ,US?P-4P9T<_P`4L5FRO8[MG)_^GR/(GS_?.EGKH>QM01\L M-Y'I;BQ<-O&-ED2UDFROO('H-A`IV#;[RWL!&?RX[!3K`LU_KUQT>I?KG>P.)U4:*EJH*C@(ARS)(E12@02R@1@'[ M;R=`UV1[FX\@-K7TE.C(O"=#1& M5>BI*IK3RLF`"EL6[9N(P"LH0;0;UQ`$F[B%'6>G39KX/`B:S9>.7Q+-9[1_ M2*FY7_.DOAR[G'28LY>(KW<5B$!:!LJ"0ZJ)7];V-Z@'%I*2!<)>)PMGB-Q= M5`(;0^"]2B8IL1(.F5_I8J?]7;M,*8%+#4>'/O9SC;BY3.UGKV8-^%MGN&DK M`4DQ>2UWM\O(2U`QI?Z_I[BR/'=`Z)Y$"?O48ZYTV(^;(V?C/N]!E->J%Y+Z M"5!R<]G+&PQ,.[U(-8/:FQO+BDN9?WM67Z>2.Z5+VC+9LZ3*E^FG:V(Q@@SZA)3>W]33!5%'3;PF`H[>C70?:@2R M,AWJKY#EF?G+HWQ9W"@#SNZG?(GO_P#.J5_BKM/`$HZ`(Q^>_*`P6SHRM470 MF9:T]G\GKBT.E@E@MN!Q]YT5:7D_BCGV_[B#]49ME24I?Z[#V'WL&NOJ(9@_\RB,1HEQ: M=/6DEHY6\8<]W[PK[DI)JYC1SL$*Q[5=:FI-^J?61UBG)5E^##.U+M0B/_\` M#:*&X>T=JZ%4\49A'`ST_HUG3N9FLY98[\UC^+D6,)/)_S9;#?%@VHHK2G MX)((M-QB+F,,15>N,#RG(="*DH,RK2[@!24VPQDM`U%>$--X=FS5LG[5V\C.X4AA'B;(OXZ:YTNF<(V?9]K`!30=BF`"8S,$0`>$``/AL1 M'01T#740CYCT5TO;Z!/YE3!)QW\?VYBT;AVF[^3.:%@F0G4]NF"UT>[-2VM4 M>D:AZPJ=:-OBB<.A5OAUEKP2]V@`(#IKJ.W7Z5J?6-C:T_`GDN$W\#,2IPVB M+;?F;V3+VUZIN-4L"GI@TI$JWNK;3:#34=1'>/V8X6R_,-ZO54G%]W].4]ZJ MRXC\\,4]_P`C'FVRG=-<6G(^%]'[4+-8X:T5!3`%O:AZFW:=G]`$/''U_06Z M]#S7E^C,K)\9S3KGS?W3V6O^9;9?'3;V+DC"9^ZAT=$L6]S@H:Z33*-!5/"S ME%5TE52=8IE>F"AO\`#;J4=_3LUVP!\?S>.[X^\*ET9&X!M4:BGJ]5I^8R)0 M><`@.@K-D/&7^*V[]ZOWNB0G$K=0IY3+;(UNY7W/B=]G$NEQ0SI=:ZMVOJ*5 M38#:O7$[Q#Z?J4Z8Q-0EK*,5ZUWGT.34KNQD5.O%OL7NE9V M`Y@G>8A_[6Y;CY.7$\-NODLI$'PS\&62I??F,7I8M]*WF M(LFYK1=""[&52VUI+G6,5K)UU6C*:,MBX9R/)%"E=HR4T_T91,`&&68P!YH& M$8U+"G4=51W#*,VT9:?W"ZRVY$6_NU>+62MB;YV:0 M%FQ:6@(BM=:T%Q+*#/.AM]8FXR[>TC`\ MM#E[YPXW\UG'TMV\9+X(;9MG<=3HW#CNC!T+R(D7>+^6[DODZ];/9&8YV\6;M]C MK<*ML7VR6G2BHNBB3`6P7D5914`X%,_3%.N5X"3:)=WDS!LJ-3E:N%-FH"J; M.9&=XKQYMNQ[)VFQ]R?0K>6Y1BMEH(0X(EKPH$HIM0$5]P64TTU$?%M@DVX+ M,UU:M.K25);83S`.\PU9_13K4Y7@39]\\N%X`7Z864`(S";@S,VHSU8K MPN&WRFK"1RY>:OS";JM)POIXHP76O#>.UY;)MIOIB29`0%=91$) MP-W4!G-Y$T+V3]T.Z-8,K9Z4U3/,LEJ.BDTE+(HI/WO34P4I0UV\)0*&WHUT M#VX'5D=?O)EF+QWSPZM(UK)VHN=>!T)V0:,N5B#:IBNFXCEHTTK*?4F8LF0F MZW'7,%#ES#$`XF*4`$Y"AMV0!T^[3V1O18C$6]S6O=:&Z=FG$IY&JB^E-^ZK M$=5N5.L2_5JP&_*6$9`/%JPMSE^OJ7"_:*V%U[4VP)?Q.JF&^7GJ=$7T4C>_:QEML=HJJ3L\/3& M].Z=9PACMR.*UKZVW<5G'@GWF8?[0?O,,O[WM=E<;4>CEK/`?!_(I$U6RFQF MF2[7#[6B)I5YJ$83>+U+N.Y)SV[S;-E:>JO*H/\`&N76L%W].GJ3B/@=+);7 MBLYL<_V>\RUR4^6YG37\P1$S6REL^X[/I;1MVFC6V1MFCT;JMG9:Y3V;B@K("2O%G MHG7:`WYC:XI5 MN--\9;!1V'BT"(A6?HZ10*[+;(9Y::XZ^8>9,5RE(MK\TX+R$)S"3JO8)A,` M!KN#BNHNFZU*BYJ#P<>'ISF+-38PFSV[11TC$+)>L4.J_4G<:FJ/?0TOONK; MBP*;Z/[OKS787Q[H^+7O2-_>U7%[^$O\:-XH8KBERV5E.6:![Y#R$R5U56#6 MI%OZ(2J9*TXG?RU5G5EJST7ETY24YC"67IL*81#0-8DG@*L[LCC MW?K']G99TE]K)7BLK7.MUV>K&NGW6MP]K<35_J)%?4M>,AE?#9:L]>)+/42^ M,Y2CZ,#`(Z!I`$J6?+DS9/HIP<1=VFNGL[H]4IO%@:4Y?/4&1S.;;R+;:YLT MB]?&P5&EVMR>&C-5K&M+U8RKTGU`"2WN3A'J-QS/.$JJ`^=LZRX@'6-XP*Z] MT>2=-R9_=\PF_D)X3Y>XZ\QJ2J7SQBO?;5KMZUERV=6O9P6Y=U#;*L511F\B MR9B*]^SP-A>!U=1@<-H"(!J&V/%RS2OXDTRF_+^M/4M)G54'%YJ&3]&3)Y0# MYP#X=`]H(RU@=--\-;#> EX-99.1 3 v137870_ex99-1.htm
Exhibit 99.1
 
Encision Reports Third Fiscal Quarter Results; Net Income Increases 295%
 
BOULDER, Colo., Jan. 27 /PRNewswire-FirstCall/ -- Encision Inc. (OTC Bulletin Board: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its third quarter ended December 31, 2008.

Net sales for the third quarter of fiscal year 2009, ended December 31, 2008, totaled $3.27 million, representing a 4% increase over net sales of $3.13 million for the prior fiscal year’s third quarter. The Company recorded net income of $233 thousand or $.04 per share for the third quarter of fiscal year 2009, representing a 295% increase, compared to net income of $59 thousand or $.01 per share for the third quarter of fiscal year 2008. Gross profit margin for the third quarter of fiscal year 2009 was 64% as compared to 65% for the third quarter of fiscal year 2008. The gross profit margin decrease from the third quarter of fiscal year 2008 was due to increased sales of lower gross profit margin products and a 0.8% increase to gross profit margin that was attributed to a decrease in warranty claims in the third quarter of fiscal year 2008.

Net sales for the first nine months of fiscal year 2009, ended December 31, 2008, totaled $9.7 million, representing a 9% increase over net sales of $8.9 million for the prior fiscal year’s first nine months. The Company recorded net income of $144 thousand or $.02 per share for the first nine months of fiscal year 2009 compared to a net loss of $228 thousand or $.04 per share for the first nine months of fiscal year 2008. Gross profit margin for the first nine months of fiscal year 2009 was 62% as compared to 63% for the first nine months of fiscal year 2008.

“All disposable scissor inserts sales made in the third quarter ending December 31, 2008 were sales from internally manufactured disposable scissor inserts and resulted in higher gross profit margins from the second quarter ended September 30, 2008. Also, we saw during this third quarter the savings effect of our reduced cost structure as it relates to engineering projects,” said Jack Serino, President and CEO of Encision Inc. “We are pleased with our net income increase of 295% and are cautiously optimistic that the results for the last three months of fiscal year 2009 will be positive.”

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.
 
CONTACT:   Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com

 
 

 
 
Encision Inc.
Condensed Statements of Operations
(Unaudited)
(Amounts in thousands, except per share information)

   
Three Months Ended
   
Nine Months Ended
 
   
Dec. 31,
   
Dec. 31,
   
Dec. 31,
   
Dec. 31,
 
   
2008
   
2007
   
2008
   
2007
 
NET SALES
  $ 3,271     $ 3,131     $ 9,711     $ 8,883  
COST OF SALES
    1,192       1,103       3,715       3,301  
GROSS PROFIT
    2,079       2,028       5,996       5,582  
OPERATING EXPENSES:
                               
Sales and marketing
    1,191       1,305       3,887       3,755  
General and administrative
    355       331       1,080       1,053  
Research and development
    286       325       856       989  
Total operating expenses
    1,832       1,961       5,823       5,797  
OPERATING INCOME (LOSS)
    247       67       173       (215 )
Interest and other income (expense), net
    (14 )     (8 )     (29 )     (13 )
INCOME (LOSS) BEFORE PROVISION FOR  INCOME TAXES
    233       59       144       (228 )
Provision for income taxes
    ––       ––       ––       ––  
NET INCOME (LOSS)
  $ 233     $ 59     $ 144     $ (228 )
Net income (loss) per share-basic and diluted
  $ 0.04     $ 0.01     $ 0.02     $ (0.04 )

 
Encision Inc.
Condensed Balance Sheets
(Amounts in thousands)
 
   
Dec. 31,
   
March 31,
 
   
2008
   
2008
 
   
(unaudited)
   
(audited)
 
ASSETS
           
Cash and cash equivalents
  $ 72     $ 71  
Accounts receivable, net
    1,433       1,453  
Inventories, net
    2,098       2,271  
Prepaid expenses
    102       99  
Total current assets
    3,705       3,894  
Equipment, net
    811       798  
Patents, net
    218       199  
Other assets
    32       53  
TOTAL ASSETS
  $ 4,766     $ 4,944  
LIABILITIES AND SHAREHOLDERS’ EQUITY
               
Accounts payable
  $ 673     $ 537  
Accrued compensation
    293       392  
Other accrued liabilities
    393       481  
Line of credit
    199       --  
Total current liabilities
    1,558       1,410  
Long-term debt
    --       606  
Common stock and additional paid-in capital
    19,523       19,387  
Accumulated (deficit)
    (16,315 )     (16,459 )
Total shareholders’ equity
    3,208       2,928  
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
  $ 4,766     $ 4,944  
 
CONTACT:   Marcia McHaffie of Encision Inc., +1-303-444-2600, mmchaffie@encision.com
 
 
 

 

-----END PRIVACY-ENHANCED MESSAGE-----